← SynDRA
BRIGATINIB
SynDRA canonical compound SYN0038271 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ALK | EGFR |
|---|
| Mechanism of action | ALK tyrosine kinase receptor inhibitor |
|---|
All known targets
- ALK
- EGFR
- IGF1R
- INSR
- ROS1
- FLT3
- NUAK1
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- IGF1R INHIBITOR
- INSR INHIBITOR
- ALK MODULATOR
Drug classes
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 3A Inducers
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- alunbrig
- AP26113
- AP-26113
- Alunbrig
- BRIGATINIB (AP-26113)
- BRIGATINIB (AP26113)
- BRIGATINIBAP-26113AP26113CS-4278
- UNII-HYW8DB273J
- Brigatinib [USAN]
- ALUNBRIG
- HYW8DB273J
- Brigatinib (USAN)
- Brigatiib
- Alunbrig (TN)
- Brigatinib [USAN:INN]
- Brigatinib (AP26113)
- SCHEMBL11916361
- KS-00000TSQ
- EX-A775
- MolPort-044-561-640
- BDBM50185140
- ZINC148723177
- AKOS030257612
- CS-4278
- DB12267
- HY-12857
- AC-29958
- ALK-IN-1
- UNII-3DGD69C6PV
- 3DGD69C6PV
- CHEMBL3397300
- (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
- 5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine
- 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine
- AP26113-analog
- Tube723
- compound 11q [PMID: 27144831]
- Brigatinib(AP26113)
Reported adverse events
- Abdominal pain
- Arthralgia
- Bradycardia
- Constipation
- Cough
- Dizziness
- Dysgeusia
- Dyspepsia
- Fatigue
- Headache
- Hypertension
- Insomnia
Look up BRIGATINIB in the interactive SynDRA portal →